What to tell your board while an FDA inspection is ongoing

During an ongoing FDA inspection, your board needs a clear account of what is known, what is being requested, what management is doing, and what remains uncertain. An early update should not invent a final outcome.

Label the update as a point-in-time report

State when the update was prepared, which site and activities are involved, and who is coordinating the response. Distinguish a request for information, an investigator’s question, a verified operational fact, and management’s working assessment. They are different kinds of information.

Explain the work without predicting the result

A practical internal briefing can cover:

• The inspection scope as currently understood and any clarification still needed.
• Important requests and the status of record retrieval and review.
• Issues management has independently identified and the evidence supporting its current assessment.
• Immediate protective actions or operating decisions, with the relevant rationale and owner.
• Resource or governance decisions that require board attention.

Keep open questions visible

Do not convert an informal exchange into a confirmed finding, root cause, agency position, or inspection classification. FDA explains that a Form 483 is issued at the conclusion of an inspection when applicable and is not itself a final agency compliance determination. While an inspection is ongoing, avoid briefing a document or decision that has not been issued.

Agree the communication process

Set an appropriate update cadence with management and relevant quality, regulatory, and legal advisers. Use authorized, consistent information and suitable confidentiality controls. Escalate a material change based on its significance rather than wait for a routine update, while obtaining advice appropriate to the company’s obligations.

The briefing should support oversight and decisions, not coach anyone to withhold, alter, backdate, or improvise records. Preserve the distinction between verified evidence and expectations.

Source context, reviewed October 20, 2026: FDA Form 483 FAQ. This article offers an independent communication framework, not an official FDA briefing requirement or a disclosure-law opinion.

Continue the leadership series

Teach your board about GMP · Educate investors about regulatory status · Brief the inspection after it closes · Board advisory support · Proposed webinars and courses.